In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:Importance of germline and somatic testingAdverse events associated with PARP inhibitorsMaintenance therapy in pancreatic cancerPresenters:Philip Agop Philip, MD, PhD, FRCPProfessorSchool of MedicineWayne State UniversityLeader, Gastrointestinal Multidisciplinary TeamDepartment of OncologyKarmanos Cancer InstituteDetroit, MichiganElena Gabriela Chiorean, MDProfessor of MedicineDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonMemberFred Hutchinson Cancer ResearchSeattle, WashingtonContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program:https://bit.ly/3jEehCcLink to associated downloadable PDF:https://bit.ly/3nSfTcR

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related